Samuel Allen Brown

US Patent:

20060122171, Jun 8, 2006

Filed:

Nov 14, 2003

Appl. No.:

10/533555

Inventors:

Wei Xu - Danville CA, US
Lynne Canne Bannen - Pacifica CA, US
Samuel Brown - San Carlos CA, US
Erick Co - Redwood City CA, US
John Nuss - Danville CA, US
Moon Kim - Palo Alto CA, US
Rhett Klein - San francisco CA, US
Donna Lee - San Jose CA, US
Amy Tsuhako - Milpitas CA, US
Morrison Mac - San Francisco CA, US
Jason Parks - Sacramento CA, US
Zhaoyang Wen - San Francisco CA, US
Wei Cheng - San Jose CA, US

International Classification:

A61K 31/55
A61K 31/454
C07D 403/14

US Classification:

514217090, 514322000, 540603000, 546199000, 546201000

Abstract:

The present invention provides compounds for modulating protein kinase enzymatic activity for modulating cellular activities such as proliferation, differentiation, programmed cell death, migration and chemoinvasion. More specifically, the invention provides oxindole derivatives which inhibit, regulate and/or modulate kinase receptor, particularly VEGF receptor 2 (Flk-1/KDR), FGFR1, and PDGFR (alpha and beta), signal transduction pathways related to the changes in cellular activities as mentioned above, compositions which contain these compounds, and methods of using them to treat kinase-dependent diseases and conditions.

US Patent:

20210213006, Jul 15, 2021

Filed:

Aug 27, 2019

Appl. No.:

17/271883

Inventors:

- Seattle WA, US
Kathleen Ann ELIAS - San Francisco CA, US
Samuel David BROWN - San Carlos CA, US
Terence Graham PORTER - Chicago IL, US
Neil Dwayne MCDONNELL - Seattle WA, US

International Classification:

A61K 31/4439
A61P 25/28

Abstract:

Described herein are methods of treating or preventing an ASK1 or DYRK1A associated disease, disorder, or condition comprising administering to a subject in need thereof a dual inhibitor of ASK1 and DYRK1A; including administering pharmaceutically acceptable salts and solvates thereof.

US Patent:

20170360760, Dec 21, 2017

Filed:

Dec 16, 2015

Appl. No.:

15/534166

Inventors:

- Calgary, CA
Peter Ronald YOUNG - San Francisco CA, US
Samuel David BROWN - San Carlos CA, US
Bryan Cordell DUFFY - Glenmont NY, US
Shuang LIU - Schenectady NY, US
Peter GUZZO - Niskayuna NY, US

International Classification:

A61K 31/422
C07D 413/04
A61K 31/435
A61K 31/4184
A61K 45/00
C07D 413/14
C07D 261/06

Abstract:

The present disclosure relates to compounds capable of acting as covalent inhibitors of bromodomains and the therapeutic use of these inhibitors.